Business Wire

NY-SNOWPLUS

4.6.2021 01:02:05 CEST | Business Wire | Press release

Share
Snowplus Experiences Global Growth Despite COVID

Snowplus , a leading global vape company, and its global business have flourished despite challenges posed by the COVID pandemic that has impacted business around the world. Their strategy of localization implemented in late 2019 has proven to be the key to their continual growth in the face of the pandemic. Since the pandemic started they have still seen a growth increase of around 350% in their global business.

Business impacts of the pandemic have been far reaching, including but not limited to logistics, manufacturing, and local economies being shut down. For the vape industry, it has been no different. However, localized strategies have enabled responsive and agile decision making, and have also minimized any negative impact from the current unforeseen global crisis.

Local Partners

In multiple new markets Snowplus has expanded to, they’ve been able to partner with leading companies that know their local markets well. To win the confidence of top level partners, a combination of quality products, reliable support, and long term investment have proven to be the key.

“Our focus on producing consistently high quality, rigorously tested products have helped us win major partnerships in markets we expand to,” explained Derek Li, Snowplus Cofounder and Head of Overseas Markets. “It’s always a satisfying moment when potential partners test our products, have a ‘wow’ moment, and come back to us ready to work something out.”

Local Strategies

In Canada, Snowplus realized quickly that finding a respected local e-liquid partner would bring down costs associated with e-liquid production and international shipping. But even more importantly, the Canadian palate was quite different from the flavors that make Snowplus pods a hit in Asia. Instead of hoping to have the market warm up to different taste profiles, tailoring flavors that fit local vapers has netted immediate market growth.

In fact, Canada is not the only market where Snowplus implements this two-pronged strategy of establishing local partners and executing local strategies. As a result, not only is Snowplus one of the fastest growing vape brands in the world according to device shipments since they started in 2019, they’ve achieved record growth during the pandemic.

“From our 28-point testing, the most thorough in the industry, to our high-tech laboratories in Shenzhen, our dogged dedication to product quality has opened doors for us in new markets and won over market leading partners wherever we go,” said Li. “In turn, it's been relatively easy for us to work with our local partners and trust their strategies, which has really carried us through this past year of difficulty. In the end, to still achieve record growth has been something we’re extremely proud of and grateful for. We’re not done. As the world slowly emerges from the pandemic, we’re open to any partners that are ready to work with us. Just reach out.”

ABOUT SNOWPLUS

Founded in April 2019, Snowplus is dedicated to replacing combustible tobacco through consistent quality and a commitment to innovating better vaping experiences. Snowplus products have passed a number of third-party safety certifications and are made with components that meet the highest medical safety standards. To date, Snowplus has received over $150 million in financing which is among the largest funding for any startup in the e-cigarette industry.

To learn more about Snowplus, please go to snowplustech.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye